Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 Combinations in Bone and Soft Tissue Sarcoma
NCT06699576Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label trial of risvutatug rezetecan in osteosarcoma (OS) and soft tissue sarcoma (STS) (4 cohorts), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose at 21 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06699576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699576.